Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711818 | 0.91 | DRD2 (0.58) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 | |
| SCHEMBL5183532 | 0.90 | ADRA1D (0.44) | PPARDPPARASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4710392 | 0.88 | HTT (0.52) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 | |
| SCHEMBL4709107 | 0.86 | LMNA (0.55) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 | |
| SCHEMBL11181299 | 0.85 | LMNA (0.64) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL11187904 | 0.84 | LMNA (0.62) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 | |
| SCHEMBL4712671 | 0.83 | LMNA (0.60) | PPARDSMN1; SMN2ALDH1A1KDM4EDRD2 | |
| SCHEMBL5183039 | 0.81 | EBP (0.50) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 | |
| SCHEMBL5183526 | 0.80 | HSD17B10 (0.45) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL5182420 | 0.79 | EBP (0.54) | SMN1; SMN2ALDH1A1KDM4EDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | claimed |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN | 2006-10-12 | — | — | US | claimed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | claimed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080044353-A1 | Combination Therapy for Weight Management | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1729762-A4 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1729762-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN | 2006-10-12 | — | — | US | disclosed |
| US-7081458-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORP. (US) | 2006-07-25 | — | — | US | disclosed |
| WO-2005094305-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6953801-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION | 2005-03-24 | — | — | US | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044353-A1 | Combination Therapy for Weight Management | CNR1, CNR2, MCHR1 | PPARD 466/4885PPARA 446/4885SMN1; SMN2 1643/4885 |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | PPARD 580/4885PPARA 695/4885SMN1; SMN2 1441/4885 |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | MCHR1, MCHR2, MC1R | PPARD 580/4885PPARA 695/4885SMN1; SMN2 1441/4885 |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | PPARD 580/4885PPARA 695/4885SMN1; SMN2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.